Home » EPIC Archives: AVCT

AVCT News Archives

Avacta Group Plc Wake-up call for the market

Hardman & Co

Avacta Group Plc (LON: AVCT) is a pre-clinical stage biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology. The significant ...

Read Article »

Avacta In vivo expression of Affimers

Hardman & Co

Avacta Plc (LON:AVCT) is a pre-clinical biotechnology company and the proprietary owner of Affimer technology. Affimers represent a radical alternative to the established antibody technology, which continues to dominate the ...

Read Article »

Avacta Group Affimer Drug Conjugates a reality

Hardman & Co

Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology ...

Read Article »

Avacta Group R&D accelerated to advance assets

Hardman & Co

Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology ...

Read Article »

Avacta Group Plc Another important box ticked

Hardman & Co

Avacta Group Plc (LON:AVCT) is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology ...

Read Article »